Lorazepam is a benzodiazepine medication developed by DJ Richards. It went on the market in the United States in 1977. Lorazepam is commonly used as the sedative and anxiolytic of choice in the inpatient setting owing to its fast (1 to 3 minute) onset of action when administered intravenously. Lorazepam is also one of the few sedative-hypnotics with a relatively clean side effect profile. Lorazepam is FDA approved for short-term (4 months) relief of anxiety symptoms related to anxiety disorders, anxiety-associated insomnia, anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia, and treatment of status epilepticus. Off-label (non-FDA-approved) uses for Lorazepam include rapid tranquilization of the agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting (adjunct or breakthrough), as well as psychogenic catatonia.
Lorazepam binds to benzodiazepine receptors on the postsynaptic GABA-A ligand-gated chloride channel neuron at several sites within the central nervous system (CNS) and enhances the inhibitory effects of GABA, which increases the conductance of chloride ions into the cell. This shift in chloride ions results in hyperpolarization and stabilization of the cellular plasma membrane. Its inhibitory action in the amygdala helps with anxiety disorders while its inhibitory action in the cerebral cortex helps in seizure disorders.
Lorazepam has an 85% bioavailability when taken by mouth and is metabolized in the liver by glucuronidation using the CYP450 enzymes and has a half-life of 14 hours. Lorazepam can be administered orally, intravenously (IV), or intramuscularly (IM). The onset of its action is 1 to 3 minutes if administered IV and 15 to 30 minutes if administered IM. Lorazepam reaches its peak plasma time in 2 hours if administered orally.
Anxiety disorder: Initial starting dose: 2 mg to 3 mg by mouth, can repeat dose 2 to 3 times per day Maximum dosage 10 mg per day.
Insomnia due to anxiety or stress: In patients less than 65 years of age: 0.5 to 2 mg at bedtime In patients over 65 years age: 0.5 to 1 mg at bedtime.
Premedication for anesthesia: IM 0.05 mg/kg administered 2 hours prior to surgery (maximum dose 4 mg); IV 0.044 mg/kg administered 15 to 20 minutes prior to surgery (maximum dose 4 mg). Note: In patients older than 50 years of age, maximum dosage is 2 mg.
Status epilepticus: IV 0.1 mg/kg (maximum dose 4 mg), at a maximum rate of 2 mg per minute; may repeat in 5 to 10 minutes Note: Must dilute dose with 1:1 saline.
Agitation in the intensive care unit (ICU) patient (off-label use): IV Loading dose 0.02 to 0.04 mg/kg (maximum single dose 2 mg); Maintenance 0.02 to 0.06 mg/kg every 2 to 6 hours as needed or 0.01 to 0.1 mg/kg per hour with a maximum dosing of less than 10 mg per hour.
Alcohol withdrawal delirium (off-label use: IV 1 to 4 mg every 5 to 15 minutes until the patient is calm; Can repeat every hour as need; IM 1 to 4 mg every 30 to 60 minutes until the patient is calm; Can repeat every hour as needed.
Alcohol withdrawal syndrome (off-label use): Symptom-triggered regimen: Oral, IM, IV 2 mg to 4 mg per hour as needed; dose must be determined by the severity assessment scale. Fixed-dose regimen: Oral, IM, IV 2 mg every 6 hours for 4 doses, followed by 1 mg every 6 hours for 8 additional doses. Note: Symptom-triggered regimen is preferred over the fixed-dose regimens; lower doses and shorter duration of treatment are needed.
For chemotherapy-associated nausea and vomiting (off-label use): For breakthrough nausea/vomiting or as an adjunct to standard antiemetics oral, IV, sublingual: 0.5 to 2 mg every 6 hours as needed.
For psychogenic catatonia (off-label use): IM 1 mg to 2 mg; can repeat dose in 3 hours then again in another 3 hours if initial and subsequent doses are ineffective; Oral, IM, IV: Initially 1 mg and may repeat in 5 minutes if necessary. If the initial challenge is unsuccessful, may increase the dose up to 4 to 8 mg per day and may continue treatment for up to 5 days.
Like most benzodiazepines, adverse reactions to lorazepam include CNS and respiratory depression, which are dose-dependent. More severe effects occur with high doses.
Serious adverse effects of lorazepam include:
Common adverse effects of lorazepam include:
Lorazepam is contraindicated in patients with an anaphylactic reaction to lorazepam, any component of the formulation, other benzodiazepines (cross-sensitivity with other benzodiazepines may exist), intra-arterial administration, use in neonates or infants, severe respiratory impairment (except during mechanical ventilation), pregnancy (third trimester), and acute narrow-angle glaucoma, severe respiratory insufficiency. Additional contraindications include Hypersensitivity to polyethylene glycol, propylene glycol, or benzyl alcohol, and sleep apnea. It can cause “floppy infant syndrome” due to neonatal withdrawal.
Monitor respiratory and cardiovascular status, blood pressure, heart rate, and symptoms of anxiety. With Long-term therapy, monitor CBC, liver function tests, and LDH. With high-dose or continuous IV use or IV use in patients with renal impairment, monitor clinical signs of propylene glycol toxicity, serum creatinine, BUN, serum lactate, and osmolality gap. With critically ill patients, monitor the depth of sedation. Lorazepam is a Schedule IV drug and patients may develop dependence and tolerance with long-term use. It is recommended to use the lowest possible effective dose for the shortest period. When stopping Lorazepam, it should be tapered by 0.5 mg every 3 days to avoid withdrawal symptoms.
Lorazepam can cause CNS and respiratory depression in overdose. It can lead to hypotension, ataxia, confusion, coma and can be fatal. Concurrent use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Concomitant prescribing of benzodiazepines and opioids must be reserved for patients for whom alternative treatment options are inadequate. Dosages and durations of Lorazepam must be limited to the minimum required. Patients must be followed for signs and symptoms of respiratory depression. Lorazepam, as with other benzodiazepines, is rarely associated with elevations in serum ALT, and clinically apparent liver injury from lorazepam is extremely rare. The clinical pattern of acute liver injury from benzodiazepines is typically cholestatic. Flumazenil is used as an antidote to benzodiazepine toxicity. Flumazenil competes with benzodiazepines for binding at the GABA/benzodiazepine receptor complex. Abrupt awakening can cause dysphoria, agitation, and increased adverse effects. If it is administered to patients who have received a benzodiazepine chronically, abrupt interruption of benzodiazepine antagonism by flumazenil can induce benzodiazepine withdrawal including seizures. Flumazenil has minimal effects on benzodiazepine-induced respiratory depression, and suitable ventilatory support should be available in treating acute benzodiazepine overdose.
Lorazepam, like other benzodiazepine medications, is a highly addictive medication. Great care must be taken when prescribing lorazepam at high doses or prolonged durations, particularly in patients with a history of substance use disorder or concurrent opioid prescriptions. Managing such patients requires an inter-professional team of healthcare professionals that include nurses, pharmacists, and a number of specialist physicians to monitor for signs of abuse, diversion or concomitant use with other prescription or non-prescription sedative medications. Prescribing physicians must be vigilant in prescribing benzodiazepine such as lorazepam and make use of State and Federal controlled substance monitoring and diversion databases to identify high-risk patients with multiple and frequent prescriptions for benzodiazepines, opioids, muscle relaxants, and other sedative-hypnotics.